Tackling Existential Crisis

In this episode of the Med City Pivot Podcast, host Arundhati Parmar speaks with Lars Petersen about one of the most remarkable corporate transformations in modern business history.

Facing a catastrophic collapse of its core film business in the mid-2000s due to the rise of digital photography, Fujifilm executed a bold and strategic pivot into healthcare and life sciences. The company diversified aggressively, leveraging its deep expertise in materials science, imaging, and innovation to build a thriving biotechnology and medical technology ecosystem.

Today, Fujifilm operates as a global Contract Development and Manufacturing Organization (CDMO), partnering with leading pharmaceutical companies and startups alike. The conversation explores how strategic investment, diversification, long-term thinking, and innovation—including AI—enabled Fujifilm not just to survive, but to lead in a completely new industry.

• Connect with Arundhati Parmar

• aparmar@medcitynews.com

• https://twitter.com/aparmarbb?lang=en

• https://medcitynews.com/

Fujifilm Pivot Healthcare CDMO Biotechnology Biologics digital transformation business strategy Innovation AI in healthcare Pharma Manufacturing monoclonal antibodies gene therapy cell therapy Diversification corporate strategy MedTech

• 00:00–00:23 – Introduction to the concept of "pivot" and Fujifilm's survival story

• 00:00–00:47 – The collapse of the film industry and existential crisis

• 00:00–01:15 – Fujifilm's transformation into a healthcare company

• 00:02:39–00:03:28 – 2006: the pivotal year and 60% revenue loss

• 00:03:28–00:03:45 – Strategic decision to diversify long-term

• 00:04:22–00:05:08 – Why Fujifilm succeeded while competitors failed

• 00:05:35–00:06:26 – Key investments and acquisitions (including Biogen assets)

• 00:06:52–00:07:30 – Why healthcare is a stable, long-term growth industry

• 00:07:53–00:08:29 – Expansion into medical devices and imaging technologies

• 00:09:42–00:10:34 – Core therapeutic focus: biologics, gene therapy, cell therapy

• 00:10:49–00:11:22 – Serving both startups and global pharma giants

• 00:12:39–00:13:40 – Competitive positioning vs. Samsung Biologics & Lonza

• 00:15:08–00:15:44 – "Partners for life" philosophy and long-term trust

• 00:17:52–00:18:49 – AI integration across manufacturing ecosystems

• 00:18:54–00:19:42 – Final takeaway: building shared ecosystems for the future of medicine